PureTech established the underlying programs and platforms that resulted in 29 therapeutic and therapeutic candidates generated from PureTech's R&D engine, including three taken from inception at PureTech to FDA approval.
Neuropsychiatric conditions
31.5% Equity and 3-5% tiered royalties on Glyph product net sales; modest regulatory and commercial milestone payments
Phase 2
See Our Program
Conditions involving inflammation and fibrosis, including idiopathic pulmonary fibrosis
100% Equity
Phase 2b completed
See Our Program
Cobenfy™ (formerly known as KarXT) Now FDA Approved for the Treatment of Schizophrenia in Adults
PureTech retains rights to certain regulatory and commercial milestone payments related to Cobenfy™ in addition to 2% royalties on annual Cobenfy sales above $2B1
FDA Approved
See Our Program
Myeloid malignancies, such as relapsed/refractory (R/R) high-risk (HR) myelodysplastic syndrome and R/R acute myeloid leukemia (AML)
100% Equity
Phase 1/2
See Our Program

1As of March 22, 2023, PureTech has sold its right to receive a 3% royalty from Karuna to Royalty Pharma on net sales up to $2 billion annually, after which threshold PureTech will receive 67% of the royalty payments and Royalty Pharma will receive 33%. Additionally, under its license agreement with Karuna/BMS, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.

Note: Relevant ownership in Celea Therapeutics and Gallop Oncology as of December 31, 2025. PureTech controls Celea Therapeutics and Gallop Oncology, Inc. Relevant ownership in Seaport Therapeutics is as of May 1, 2026.

PureTech Level Cash, Cash Equivalents

$248.1M
PureTech Level Cash, Cash Equivalents as of March 31, 20261
1 PureTech level cash and cash equivalents as of March 31, 2026, is an unaudited figure and excludes cash and cash equivalents at non-wholly owned subsidiary of $0.1m. PureTech level cash and cash equivalents is a non-IFRS measure.

Developing breakthrough medicines at PureTech